Overview

Bioequivalence Study of Two Formulations of Propafenone 300 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions

Status:
Completed

Trial end date:
2019-05-08

Target enrollment:

Participant gender:

Summary

This bioequivalence study will be conducted in healthy male and female volunteers in order to determine the bioequivalence of two different formulations of propafenone after a single oral dose administration under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Pharmtechnology LLC

Collaborators:

Altasciences Company Inc.
Altasciences Company, Inc.

Treatments:

Propafenone